Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and ...

Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Thanks to Joanna from Poland, I have no measurable leukemia. Getting college-age kids to join the bone-marrow donor registry ...

The response rate in the control cohort is in line with historical data on azacitidine. Investors, already burnt by setbacks ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small ...

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...